Merck & Co. Stock News

I initiate coverage on Merck & Co., Inc. with a Strong Buy rating and a $139 price target, driven by resilient execution and robust product depth. Merck is growing pharma sales and expanding margins, led by strong KEYTRUDA performance and cost discipline. New product launches like WINREVAIR are exceeding expectations and offsetting pipeline risk.

The three pharma stocks in this analysis all look a bit mixed in the premarket, after seeing some momentum late last week. This is especially true with LLY, as you will see on the charts.

Investors love dividend stocks, especially the high-yield variety, because they offer a significant income stream and have massive total return potential.

NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Merck & Co., Inc. (NYSE: MRK) on behalf of long-term stockholders following a class action complaint that was filed against Merck on February 12, 2025 with a Class Period from February 3, 2022, to February 3, 2025. Our investiga...

Growth is driven by heightened demand for water and wastewater treatment due to water scarcity and stringent environmental regulations. Key industries like pharmaceuticals, food and beverages, and water treatment are increasingly adopting microfiltration technology for its efficiency and sustainability. However, high initial and operational costs present challenges, particularly for small-scale...

Unprecedented Opportunities: Recent market panic has created deep discounts among world-class blue-chip companies trading at 52-week lows, offering up to 100% potential returns and secure yields approaching 8%. Trade War Realities: Despite severe pessimism driven by historic tariff increases (highest since 1909), the actual economic impact might be significantly less dire, potentially avoiding ...

U.S. President Donald Trump said on Monday that he expects to impose tariffs on imported pharmaceuticals in the not-too-distant future.

NEW YORK , April 13, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Merck & Co., Inc. (NYSE: MRK) between February 3, 2022 and February 3, 2025, both dates inclusive (the "Class Period"), of the important April 14, 2025 lead plaintiff deadline. So what: If you purchased Merck securities during the Class Period you may be entitled to c...